Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 1;108(3):587-596.
doi: 10.1016/j.ijrobp.2020.05.026. Epub 2020 May 26.

Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer

Affiliations

Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective Clinical Trials for Non-Small Cell Lung Cancer

Weili Wang et al. Int J Radiat Oncol Biol Phys. .

Abstract

Purpose: To study the dosimetric risk factors for radiation-induced proximal bronchial tree (PBT) toxicity in patients treated with radiation therapy for non-small cell lung cancer (NSCLC).

Methods and materials: Patients with medically inoperable or unresectable NSCLC treated with conventionally fractionated 3-dimensional conformal radiation therapy (3DCRT) in prospective clinical trials were eligible for this study. Proximal bronchial tree (PBT) and PBT wall were contoured consistently per RTOG 1106 OAR-Atlas. The dose-volume histograms (DVHs) of physical prescription dose (DVHp) and biological effective dose (α/β = 2.5; DVH2.5) were generated, respectively. The primary endpoint was PBT toxicities, defined by CTCAE 4.0 under the terminology of bronchial stricture/atelectasis.

Results: Of 100 patients enrolled, with a median follow-up of 64 months (95% confidence interval [CI], 50-78), 73% received 70 Gy or greater and 17% developed PBT toxicity (grade 1, 8%; grade 2, 6%; grade 3, 0%; and grade 4, 3%). The median time interval between RT initiation and onset of PBT toxicity was 8.4 months (95% CI, 4.7-44.1). The combined DVHs showed that no patient with a PBT maximum physical dose <65 Gy developed any PBT toxicity. Cox proportional hazards analysis and receiver operating characteristic analysis demonstrated that V75 of PBT was the most significant dosimetric parameter for both grade 1+ (P = .035) and grade 2+ (P = .037) PBT toxicities. The dosimetric thresholds for V75 of PBT were 6.8% and 11.9% for grade 1+ and grade 2+ PBT toxicity, respectively.

Conclusions: V75 of PBT appeared be the most significant dosimetric parameter for PBT toxicity after conventionally fractionated thoracic 3DCRT. Constraining V75 of PBT can limit clinically significant PBT toxicity.

PubMed Disclaimer

Conflict of interest statement

【Conflict of Interest】

The authors declare no potential conflict of interest related to this work.

Figures

Figure 1.
Figure 1.
Combined Dose-Volume Histograms (DVHs) of proximal bronchial tree (A) and proximal bronchial tree wall (B) for 100 patients.
Figure 2.
Figure 2.
Dose-Volume Histograms (DVHs) atlas plots for (A) Grade 1+ and (B) Grade 2+ PBT toxicity.
Figure 3.
Figure 3.
Receiver operating characteristic (ROC) analysis of Dose-Volume Histograms (DVHs) parameters for PBT toxicity Grade 1+ (A, C) and Grade 2+ (B, D).
Figure 4.
Figure 4.
Kaplan-Meier cumulative incidence plots for Grade 1+ (A) and Grade 2+ (B) PBT toxicity with optimal cutoff values of V75 of PBT. PBT, proximal bronchial tree; V75, volumes receiving doses greater than 75 Gy.

Similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, et al.: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424, 2018 - PubMed
    1. Tyldesley S, Boyd C, Schulze K, et al.: Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 49:973–85, 2001 - PubMed
    1. Bradley JD, Paulus R, Komaki R, et al.: Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16:187–99, 2015 - PMC - PubMed
    1. Senan S, Brade A, Wang LH, et al.: PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 34:953–62, 2016 - PubMed
    1. Timmerman R, Paulus R, Galvin J, et al.: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070–6, 2010 - PMC - PubMed

Publication types

MeSH terms